Clinical Trials on Overactive Detrusor in Norway

Total 44 results

Astellas Pharma Inc
Astellas Pharma Europe B.V.

Completed

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron OCAS (Oral Controlled Absorption System) in Pediatric Subjects With Neurogenic Detrusor Overactivity or Overactive Bladder

Overactive Bladder | Pharmacokinetics of Mirabegron | Neurogenic Detrusor Overactivity

Belgium, Denmark, Norway, Poland, Serbia
Astellas Pharma Inc

Completed

Study of 2 Doses of Solifenacin Succinate in Female Subjects With Overactive Bladder. (SHRINK)

Overactive Bladder | Detrusor Overactivity

Belgium, Norway, Spain, Sweden, Italy, Czech Republic, Hungary, France, Canada, Germany, Austria, United Kingdom, Bulgaria, Russian Federation, United States, Poland, Slovakia, Turkey, Israel, Romania
Astellas Pharma Europe B.V.

Completed

Open-label Phase 3 Study With Mirabegron in Children From 3 to Less Than 18 Years of Age With Neurogenic Detrusor Overactivity (Crocodile)

Neurogenic Detrusor Overactivity

Belgium, Croatia, Turkey, Australia, Denmark, Israel, Jordan, Korea, Republic of, Latvia, Lithuania, Malaysia, Mexico, Norway, Philippines, Poland, Romania, Serbia, Slovakia, Taiwan
The Hospital of Vestfold
South-Eastern Norway Regional Health Authority

Completed

Instillation of Botox in the Bladder in Women With Overactive Bladder (OAB)

Overactive Bladder

Norway
University of Oslo

Completed

A Tetracycline Drain Reduces Alveolar Osteitis in Third Molar Surgery (Wisdomsteeth)

Post-Operative Wound Infection

Norway
Norwegian University of Science and Technology
St. Olavs Hospital

Completed

Minimal Invasive Surgery in Total Hip Arthroplasty Patients; Strength, Functionality and Post Operative Complications

Hip Osteoarthritis

Norway
Ullevaal University Hospital
University of Oslo

Completed

Postoperative Pain Course After Uvulopalatoplasty

Quality of Life | Pain, Postoperative | Snoring | Surgical Procedures, Operative

Norway
Oslo University Hospital
Sunnaas Rehabilitation Hospital

Completed

Prevention of Bladder Dysfunction in Acute Spinal Cord Injury (BOT-SCI)

Urinary Bladder, Overactive | Spinal Cord Injuries

Norway
Pfizer

Completed

Investigation of Tolterodine, Pregabalin and a Tolterodine - Pregabalin Combination for the Treatment of Overactive Bladder

Overactive Bladder

Czech Republic, Slovakia, United Kingdom, Sweden, Norway, Lithuania
Pfizer's Upjohn has merged with Mylan to form Viatris...

Completed

Detrol LA In Men With Overactive Bladder.

Overactive Bladder (OAB)

United States, Canada, Germany, Korea, Republic of, Spain, Turkey, Taiwan, Italy, Slovakia, Denmark, South Africa, United Kingdom, Mexico, Sweden, Norway
Allergan

Terminated

OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Overactive Bladder in Pediatric Patients (12 to 17)

Urinary Incontinence | Urinary Bladder | Overactive

United States, Australia, Belgium, Canada, Czechia, France, Germany, Italy, Netherlands, Norway, Poland, South Africa, United Kingdom
Pfizer

Completed

Fesoterodine "add-on" Male Overactive Bladder Study

Overactive Bladder Syndrome

United States, Canada, Greece, Brazil, Korea, Republic of, Singapore, Poland, India, Norway, Slovakia, Spain, Belgium, Philippines, Netherlands, Sweden, Thailand, Malaysia, Germany, Colombia
BlueWind Medical

Recruiting

BlueWind RENOVA iStim™ System for the Treatment of OAB (OASIS)

Treatment of Patients Suffering From Overactive Bladder (OAB)

United States, Belgium, Netherlands, United Kingdom
Astellas Pharma Europe Ltd.

Completed

A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin) (BESIDE)

Urologic Diseases | Urinary Bladder Diseases | Urinary Bladder Overactive

United States, Armenia, Australia, Austria, Belgium, Canada, Czechia, Denmark, Finland, France, Georgia, Germany, Greece, Hungary, Ireland, Israel, Italy, Lebanon, Netherlands, Norway, Poland, Portugal, Romania, Russian Federation, Slov... and more
Astellas Pharma Global Development, Inc.

Completed

Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB) (PILLAR)

Overactive Bladder (OAB)

United States, Canada
Astellas Pharma Inc
Astellas Pharma Europe B.V.

Completed

A Study of YM178 in Patients With Symptomatic Overactive Bladder (DRAGON)

Overactive Bladder

Poland, United Kingdom, Germany, Spain, Netherlands, Belgium, Czech Republic, Italy, Norway, Hungary, Sweden, Denmark, Greece, France, Russian Federation
Astellas Pharma Europe B.V.

Completed

A Multinational Study Comparing the Long-term Efficacy and Safety of Two Medicines, Solifenacin Succinate and Mirabegron Taken Together, or Separately, in Subjects With Symptoms of Overactive Bladder (SYNERGY II)

Overactive Bladder | Urgency Incontinence | Urinary Bladder Overactive | Urinary Bladder Diseases\Urologic Diseases

Belgium, Russian Federation, Korea, Republic of, United States, Germany, Spain, Australia, Bulgaria, Canada, Czechia, Denmark, Estonia, Finland, Hungary, Italy, Latvia, Lithuania, Malaysia, Mexico, Netherlands, New Zealand, Norway, ... and more
Astellas Pharma Europe B.V.

Completed

This Was a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive Bladder (SYNERGY)

Overactive Bladder | Urgency Incontinence | Urinary Bladder Overactive | Urinary Bladder Diseases\Urologic Diseases

United States, Argentina, Australia, Belgium, Bulgaria, Canada, China, Colombia, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Hong Kong, Hungary, Italy, Korea, Republic of, Latvia, Lithuania, Malaysia, Mexico, Netherlands and more
Pfizer

Completed

Fesoterodine Flexible Dose Study

Overactive Bladder

United States
Pfizer

Completed

A Study Of Efficacy And Safety Of Fesoterodine In Vulnerable Elderly Subjects With Overactive Bladder

Overactive Bladder

United States
Pfizer

Completed

A Trial To Evaluate The Efficacy And Safety Of Fesoterodine In Patients With Symptoms Of Overactive Bladder Including Nocturnal Urinary Urgency

Overactive Bladder

United States
Pfizer

Completed

Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine for Overactive Bladder (OAB)

Overactive Bladder

Denmark, United States, Canada, Costa Rica, Belgium, Czech Republic, Colombia, Germany, Hungary, Korea, Republic of, Spain, Chile, Taiwan, India, Brazil, Singapore, Greece, Hong Kong, Italy, Sweden, Poland, South Africa, Malaysia, Rom... and more
Pfizer

Completed

A 12 Week Study to Confirm the Effectiveness of 8mg of Fesoterodine Compared to 4mg of Fesoterodine

Overactive Bladder

Korea, Republic of, United States, Denmark, Germany, Canada, Hungary, Poland, France, United Kingdom, Slovakia, Sweden, Mexico, Czech Republic, Finland, Italy, Lithuania, Argentina, Chile, Colombia, Egypt, Greece, Norway, Philippines, Russian Federation and more
Allergan

Completed

OnabotulinumtoxinA (BOTOX®) Treatment for Urinary Incontinence in Patients With Overactive Bladder (COMFORT)

Overactive Bladder

United States
Astellas Pharma Europe B.V.

Completed

A Study to Investigate How Safe and Effective Solifenacin Solution is in Treating Children/Adolescents With Symptoms of Overactive Bladder (OAB) Who Completed Study 905-CL-076 (LEOPARD)

Urinary Bladder, Overactive

Belgium, United States, Brazil, Canada, Denmark, Former Serbia and Montenegro, Korea, Republic of, Mexico, Norway, Philippines, Poland, South Africa, Sweden, Turkey, Ukraine, United Kingdom
Pfizer's Upjohn has merged with Mylan to form Viatris...

Completed

Effect Of Detrol LA With Behavioral Intervention In Overactive Bladder Subjects Dissatisfied With Recent OAB Medication.

Urinary Incontinence

United States
Urovant Sciences GmbH

Active, not recruiting

Composur: Study to Understand the Performance of Vibegron in Participants With Overactive Bladder (OAB)

Overactive Bladder

United States
Astellas Pharma Europe B.V.

Completed

A Study to Investigate How Effective and Safe Solifenacin Succinate Suspension is in Treating Children/Adolescents Aged 5 to Less Than 18 Years With Symptoms of Overactive Bladder (OAB) Compared to a Non-active Drug (LION)

Urinary Bladder, Overactive

Belgium, United States, Brazil, Canada, Denmark, Former Serbia and Montenegro, Korea, Republic of, Mexico, Norway, Philippines, Poland, South Africa, Sweden, Turkey, Ukraine, United Kingdom
Valencia Technologies Corporation

Active, not recruiting

Pivotal Study of eCoin for Overactive Bladder With Urgency Urinary Incontinence

Overactive Bladder | Urge Incontinence | Urinary Urge Incontinence | Incontinence, Urinary

United States
Pfizer

Completed

A Study to Compare the Effectiveness and Safety of Fesoterodine and Placebo in an Elderly Population of Patients Who go to the Toilet Very Frequently Due to Overactive Bladder. (SOFIA)

Urinary Bladder, Overactive

Portugal, Spain, Turkey, Finland, Germany, Norway, Sweden, Slovakia, Italy, Austria, United Kingdom, Belgium, Denmark, Israel, Switzerland
Astellas Pharma Inc

Completed

Solifenacin Succinate Versus Tolterodine 4mg Once Daily (STAR)

Urinary Bladder, Overactive

France, United Kingdom, Spain, Belarus, Belgium, Ukraine, Denmark, Greece, Russian Federation, Czech Republic, Netherlands, Germany, Hungary, Italy, Slovakia, Sweden, Norway
Astellas Pharma Inc

Completed

Solifenacin Succinate 5mg or 10mg Once Daily in the Treatment of Urgency Symptoms (SUNRISE)

Urinary Bladder, Overactive

France, United Kingdom, Belgium, Germany, Spain, Portugal, Greece, Russian Federation, Czech Republic, Poland, Hungary, Italy, Slovakia, Egypt
Pfizer

Completed

Study The Effects Of Different Doses Of UK-369,003 In Men With Overactive Bladder

Urinary Bladder, Overactive

Australia, France, Colombia, Germany, Canada, Finland, Slovakia, Spain, Switzerland, Italy, Chile, Greece, Latvia, Norway, Poland, United Kingdom
Astellas Pharma Inc

Completed

A Multicenter VESIcare® Efficacy and Safety Study for the Treatment of Urgency Associated With Overactive Bladder (OAB) (VENUS)

Urinary Bladder, Overactive

United States
Astellas Pharma Inc

Completed

Efficacy & Safety Study of VESIcare® (Solifenacin Succinate) in Patients Wishing to Switch From Detrol LA® for Treatment of Overactive Bladder (VERSUS)

Urinary Bladder, Overactive

United States
Pfizer

Completed

A Clinical Study in Patients With Overactive Bladder With Leakage of Urine, to Find Out if the Medicine, Fesoterodine, Works in Those Patients Who Did Not Have Enough Response to the Medicine, Tolterodine.

Urinary Bladder, Overactive

Canada, United States, Germany, Russian Federation, Czechia, Egypt, Bulgaria, Finland, Hungary, Korea, Republic of, Mexico, Poland, South Africa, Sweden, Ukraine
Astellas Pharma Inc

Completed

Open-label Study of the Efficacy and Safety of VESIcare® in Patients With Overactive Bladder Symptoms (VOLT)

Urinary Bladder, Overactive

United States
Astellas Pharma Europe B.V.

Completed

A Study to Evaluate the Efficacy, Safety and Tolerability of Mirabegron and Solifenacin Succinate Alone and in Combination for the Treatment of Overactive Bladder (Symphony)

Urologic Diseases | Urinary Bladder, Overactive | Urinary Bladder Diseases | Urological Manifestations | Signs and Symptoms

Belarus, Belgium, Czechia, Denmark, Finland, France, Germany, Hungary, Italy, Netherlands, Norway, Poland, Portugal, Romania, Russian Federation, Slovakia, Spain, Sweden, Ukraine, United Kingdom
Astellas Pharma Europe Ltd.

Completed

A Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Patients With Overactive Bladder Who Were Previously Treated With Another Medicine But Were Not Satisfied With That Treatment. (BEYOND)

Urologic Diseases | Urinary Bladder, Overactive | Urinary Bladder Diseases

Greece, Ireland, Armenia, Austria, Belarus, Belgium, Bulgaria, Canada, Czechia, Denmark, Finland, France, Georgia, Germany, Hungary, Italy, Kazakhstan, Latvia, Lebanon, Lithuania, Netherlands, Norway, Poland, Portugal, Russian Federation, Slovaki... and more
Astellas Pharma Inc

Completed

A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder (CAPRICORN)

Urinary Bladder, Overactive

United States, Hungary, Canada, Spain, Finland, Slovakia, Czechia, Sweden, Germany, Denmark, Norway
Astellas Pharma Inc

Completed

Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder (SCORPIO)

Urinary Bladder, Overactive

Australia, Belgium, France, Spain, Sweden, Bulgaria, Romania, Italy, Greece, South Africa, Austria, Poland, United Kingdom, Hungary, Denmark, Netherlands, Switzerland, Ireland, Lithuania, Russian Federation, Germany, Latvia, Slovakia, Finlan... and more
Astellas Pharma Inc

Completed

Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder (TAURUS)

Urinary Bladder, Overactive

Canada, Poland, Belgium, Spain, Sweden, United States, Romania, Italy, France, Austria, United Kingdom, Germany, Hungary, Australia, Denmark, Netherlands, Switzerland, Lithuania, Russian Federation, Latvia, South Africa, Slovakia, F... and more
GlaxoSmithKline

Completed

Post-Operative Nausea And Vomiting Study In Female Patients

Postoperative Nausea and Vomiting | Nausea and Vomiting, Postoperative

United States, Spain, Philippines, Israel, Hong Kong, Thailand, United Kingdom, Hungary, Slovenia, Norway, Denmark
Medtronic

Recruiting

Product Surveillance Registry (PSR)

Coronary Artery Disease | Renal Insufficiency | Neurological Disorders | Intracranial Aneurysm | Surgical Procedures, Operative | Respiratory Therapy | Minimally Invasive Surgical Procedures | Cardiac Rhythm Disorders | Urological Disorders | Cardiovascular Disorders | Digestive Disorders | Mechanical Circulatory... and other conditions

China, France, Italy, United States, Spain, Australia, Belgium, Denmark, Germany, Greece, Hungary, Israel, Japan, Korea, Republic of, Malaysia, Netherlands, Norway, Portugal, Serbia, Sweden, Switzerland, United Kingdom, Argentina, Brazil and more

Clinical Trials on Overactive Detrusor in Norway

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Zimbabwe

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations